Cellusion
Regenerative Medicine · Cell & Gene Therapy
No open roles listed
Data updated Nov 20, 2026Money ledger: 2 records from 2 sourcesAnnounced 2Full reportReport a mistake
Facts
as of Nov 20, 2026Cellusion develops regenerative medicine therapies using induced pluripotent stem (iPS) cells focused on treating corneal endothelial diseases. The company is developing a proprietary minimally invasive cell therapy composed of corneal endothelial cells derived from iPS cells to reduce reliance on donor corneas and highly skilled surgeons. Its product targets patients with corneal blindness worldwide by enabling broader access to transplantation-like treatment options.
- Employees
- 1001-5000estimated range
- Website
- cellusion.jp
These are the key facts about Cellusion on Alion as of Nov 20, 2026. It has raised $2.8B in 2 funding rounds. The latest round is Series C of $2.8B, announced in 2023.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
Funding
Full ledger, 2 records →Cellusion has $2.8B paid in by investors, lenders and donors.
$2.8BPaid in
Money innewest first
$2.8BPaid
$9.5MPaid
Money by yearUSD, rounds and grants
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
Products
Risk
Full record →Cellusion in public registers.
No match
None
None
Patents
2
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Milestones
Raised a round Series C $2.8B · businesswire
Jun 7, 2023
Raised a round Venture round $9.5M
Jan 17, 2022
Sources: the outlets named on each headline, each story once
